TN2014000499A1 - Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide - Google Patents
Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamideInfo
- Publication number
- TN2014000499A1 TN2014000499A1 TN2014000499A TN2014000499A TN2014000499A1 TN 2014000499 A1 TN2014000499 A1 TN 2014000499A1 TN 2014000499 A TN2014000499 A TN 2014000499A TN 2014000499 A TN2014000499 A TN 2014000499A TN 2014000499 A1 TN2014000499 A1 TN 2014000499A1
- Authority
- TN
- Tunisia
- Prior art keywords
- ylmethylamino
- quinazolin
- sulfonamide
- pyridin
- pyridine
- Prior art date
Links
- XGKULQQVQWCASY-UHFFFAOYSA-N 5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine-3-sulfonamide Chemical compound NS(=O)(=O)C1=CN=CC(C=2N=C3C=CC=C(C3=C(NCC=3N=CC=CC=3)N=2)C=2C=CC=CC=2)=C1 XGKULQQVQWCASY-UHFFFAOYSA-N 0.000 title 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical compound NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 title 1
- 229940061584 phosphoramidic acid Drugs 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000004310 Ion Channels Human genes 0.000 abstract 1
- 108090000862 Ion Channels Proteins 0.000 abstract 1
- 229910018830 PO3H Inorganic materials 0.000 abstract 1
- 102000004257 Potassium Channel Human genes 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 108020001213 potassium channel Proteins 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
- C07F9/65128—Six-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261657913P | 2012-06-11 | 2012-06-11 | |
| PCT/US2013/044882 WO2013188254A1 (en) | 2012-06-11 | 2013-06-10 | Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2014000499A1 true TN2014000499A1 (en) | 2016-03-30 |
Family
ID=48670111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TN2014000499A TN2014000499A1 (en) | 2012-06-11 | 2014-11-28 | Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US9238666B2 (OSRAM) |
| EP (1) | EP2858987B1 (OSRAM) |
| JP (1) | JP6234450B2 (OSRAM) |
| KR (1) | KR102092984B1 (OSRAM) |
| CN (1) | CN104350048B (OSRAM) |
| AR (1) | AR091402A1 (OSRAM) |
| AU (1) | AU2013274619B2 (OSRAM) |
| BR (1) | BR112014030629B1 (OSRAM) |
| CA (1) | CA2876359C (OSRAM) |
| CL (1) | CL2014003361A1 (OSRAM) |
| CO (1) | CO7160032A2 (OSRAM) |
| CY (1) | CY1120432T1 (OSRAM) |
| DK (1) | DK2858987T3 (OSRAM) |
| EA (1) | EA024692B1 (OSRAM) |
| ES (1) | ES2675314T3 (OSRAM) |
| HR (1) | HRP20180815T8 (OSRAM) |
| HU (1) | HUE039210T2 (OSRAM) |
| IL (1) | IL236074A (OSRAM) |
| LT (1) | LT2858987T (OSRAM) |
| MX (1) | MX356699B (OSRAM) |
| MY (1) | MY169219A (OSRAM) |
| NZ (1) | NZ703632A (OSRAM) |
| PE (1) | PE20150228A1 (OSRAM) |
| PH (1) | PH12014502747B1 (OSRAM) |
| PL (1) | PL2858987T3 (OSRAM) |
| PT (1) | PT2858987T (OSRAM) |
| RS (1) | RS57376B1 (OSRAM) |
| SG (1) | SG11201408076WA (OSRAM) |
| SI (1) | SI2858987T1 (OSRAM) |
| SM (1) | SMT201800369T1 (OSRAM) |
| TN (1) | TN2014000499A1 (OSRAM) |
| TW (1) | TWI571470B (OSRAM) |
| WO (1) | WO2013188254A1 (OSRAM) |
| ZA (1) | ZA201500161B (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9050345B2 (en) * | 2013-03-11 | 2015-06-09 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
| WO2014143607A1 (en) * | 2013-03-11 | 2014-09-18 | Bristol-Myers Squibb Company | Pyrrolopyridazines as potassium ion channel inhibitors |
| EP2970294B1 (en) * | 2013-03-11 | 2016-12-28 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
| JP7110094B2 (ja) * | 2015-11-19 | 2022-08-01 | バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド | 医薬化合物のアミンプロドラッグ |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| GB9514380D0 (en) * | 1995-07-13 | 1995-09-13 | Knoll Ag | Therapeutic agents |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| PT1094816E (pt) | 1998-07-06 | 2009-03-10 | Bristol Myers Squibb Co | Sulfonamidas bifenílicas duplamente antagonistas receptores de angiotensina e endotelina |
| ES2215474B1 (es) | 2002-12-24 | 2005-12-16 | J. URIACH & CIA S.A. | Nuevos derivados de fosforamida. |
| AR049847A1 (es) | 2004-07-29 | 2006-09-06 | Merck & Co Inc | Inhibidores de los canales de potasio |
| KR20070092297A (ko) * | 2004-12-21 | 2007-09-12 | 데브젠 엔브이 | Ｋｖ4 이온 채널 활성을 갖는 화합물 |
| ES2900504T3 (es) | 2009-09-03 | 2022-03-17 | Bristol Myers Squibb Co | Quinazolinas como inhibidores de los canales iónicos de potasio |
| US8993552B2 (en) | 2009-09-04 | 2015-03-31 | The Regents Of The University Of Michigan | Compositions and methods for treatment of leukemia |
| AR079814A1 (es) | 2009-12-31 | 2012-02-22 | Otsuka Pharma Co Ltd | Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos |
| WO2011163594A2 (en) * | 2010-06-24 | 2011-12-29 | Alkermes, Inc. | Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
| WO2014143609A1 (en) * | 2013-03-11 | 2014-09-18 | Bristol-Myers Squibb Company | Isoquinolines as potassium ion channel inhibitors |
| US9050345B2 (en) * | 2013-03-11 | 2015-06-09 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
| US9242966B2 (en) * | 2013-03-11 | 2016-01-26 | Bristol-Myers Squibb Company | Phthalazines as potassium ion channel inhibitors |
-
2013
- 2013-06-10 AU AU2013274619A patent/AU2013274619B2/en active Active
- 2013-06-10 LT LTEP13730444.0T patent/LT2858987T/lt unknown
- 2013-06-10 NZ NZ703632A patent/NZ703632A/en unknown
- 2013-06-10 BR BR112014030629-0A patent/BR112014030629B1/pt active IP Right Grant
- 2013-06-10 RS RS20180738A patent/RS57376B1/sr unknown
- 2013-06-10 CA CA2876359A patent/CA2876359C/en active Active
- 2013-06-10 TW TW102120593A patent/TWI571470B/zh active
- 2013-06-10 SG SG11201408076WA patent/SG11201408076WA/en unknown
- 2013-06-10 WO PCT/US2013/044882 patent/WO2013188254A1/en not_active Ceased
- 2013-06-10 US US14/406,543 patent/US9238666B2/en active Active
- 2013-06-10 AR ARP130102043 patent/AR091402A1/es not_active Application Discontinuation
- 2013-06-10 EP EP13730444.0A patent/EP2858987B1/en active Active
- 2013-06-10 HU HUE13730444A patent/HUE039210T2/hu unknown
- 2013-06-10 ES ES13730444.0T patent/ES2675314T3/es active Active
- 2013-06-10 CN CN201380030478.2A patent/CN104350048B/zh active Active
- 2013-06-10 MX MX2014014525A patent/MX356699B/es active IP Right Grant
- 2013-06-10 PE PE2014002405A patent/PE20150228A1/es active IP Right Grant
- 2013-06-10 SM SM20180369T patent/SMT201800369T1/it unknown
- 2013-06-10 EA EA201492256A patent/EA024692B1/ru not_active IP Right Cessation
- 2013-06-10 MY MYPI2014703715A patent/MY169219A/en unknown
- 2013-06-10 DK DK13730444.0T patent/DK2858987T3/en active
- 2013-06-10 PL PL13730444T patent/PL2858987T3/pl unknown
- 2013-06-10 KR KR1020157000330A patent/KR102092984B1/ko active Active
- 2013-06-10 SI SI201331033T patent/SI2858987T1/en unknown
- 2013-06-10 JP JP2015517321A patent/JP6234450B2/ja active Active
- 2013-06-10 PT PT137304440T patent/PT2858987T/pt unknown
- 2013-06-10 HR HRP20180815TT patent/HRP20180815T8/hr unknown
-
2014
- 2014-11-28 TN TN2014000499A patent/TN2014000499A1/fr unknown
- 2014-12-04 IL IL236074A patent/IL236074A/en active IP Right Grant
- 2014-12-09 PH PH12014502747A patent/PH12014502747B1/en unknown
- 2014-12-10 CL CL2014003361A patent/CL2014003361A1/es unknown
-
2015
- 2015-01-08 CO CO15003999A patent/CO7160032A2/es unknown
- 2015-01-09 ZA ZA2015/00161A patent/ZA201500161B/en unknown
-
2018
- 2018-07-13 CY CY20181100733T patent/CY1120432T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012214029A8 (en) | Rorgammat inhibitors | |
| WO2014028589A3 (en) | 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| WO2014028600A3 (en) | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| MY160243A (en) | Quinazolines as potassium ion channel inhibitors | |
| MY172924A (en) | Neprilysin inhibitors | |
| PH12014502733A1 (en) | Neprilysin inhibitors | |
| MY165087A (en) | Neprilysin inhibitors | |
| JO3115B1 (ar) | مركبات بيريدازينون واستخدامها كمثبطات daao | |
| MX339873B (es) | Inhibidores de serina/treonina cinasa. | |
| MX360679B (es) | Derivados de betulina. | |
| HK1215579A1 (zh) | 被取代的2，3-二氫苯並呋喃基化合物和其用途 | |
| PH12015501755A1 (en) | Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders | |
| MX2014002936A (es) | Nuevos derivados de acido betulinico con actividad antiviral. | |
| WO2013177349A3 (en) | Quinazolinediones as tankyrase inhibitors | |
| IN2014CN04449A (OSRAM) | ||
| MX2013008340A (es) | Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer. | |
| WO2015042414A8 (en) | Multicyclic compounds and methods of using same | |
| PH12014502747A1 (en) | Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide | |
| MX359399B (es) | Inhibidores de 17alfa-hidroxilasa/c17-20-liasa. | |
| MD20160111A2 (ro) | Derivaţi diheterociclici legaţi de cicloalchil | |
| MX2013009386A (es) | Nuevos compuestos de azaespirodecanona. | |
| PH12013501897A1 (en) | Azole derivative | |
| TN2014000077A1 (en) | Pyridazinone compounds and their use as daao inhibitors | |
| HK1231074A1 (en) | Neprilysin inhibitors |